Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genzyme Firms Up Long Term, High Investment Plans For India

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - U.S. biotech Genzyme has firmed up a long-term, high-investment growth plan for India. The plan includes launch of Genzyme's entire portfolio of 15 drugs over the next three to four years, forging partnerships for research on drugs that are relevant to India, devising access programs and expanding scope of clinical trials on its experimental drugs

You may also be interested in...



In India, Sanofi-Aventis Scores Good Results But Integration With Genzyme Will Be Key To Draw Benefits From Deal

MUMBAI - It was a busy day at Sanofi-Aventis' Indian headquarters as the European firm's nine-month long pursuit to buy specialty biotech Genzyme culminated on the day its Indian arm announced its full year and fourth quarter earnings data to investors

In India, Sanofi-Aventis Scores Good Results But Integration With Genzyme Will Be Key To Draw Benefits From Deal

MUMBAI - It was a busy day at Sanofi-Aventis' Indian headquarters as the European firm's nine-month long pursuit to buy specialty biotech Genzyme culminated on the day its Indian arm announced its full year and fourth quarter earnings data to investors

India’s Advinus Signs On With Genzyme In Malaria Research

Anti-malarial drug research involving Genzyme and others is set to expand with the help of new Indian partner Advinus, just taken on board to develop early-stage candidates

Latest News
See All
UsernamePublicRestriction

Register

SC067550

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel